556PSex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

ConclusionsFrom the results of this study, oxaliplatin seems to incur transient decrease in sperm concentration with recovery, and some but not pronounced increase in FSH in males. The risk for infertility and hypogonadism in males and females after adjuvant oxaliplatin-based chemotherapy seems to be low to moderate, but the general recommendation of appropriate fertility conserving measures shall should not be changed.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureP. Ă–sterlund: Honoraria (self): Amgen; Honoraria (self): Bayer; Honoraria (self): Celgene; Honoraria (self): Eli Lilly; Honoraria (self): Merck; Honoraria (self): Nordic Drugs; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Servier; Travel / Accommodation / Expenses: Pierre Fabre ; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: AbbVie. E. Hofsli: Honoraria (self): Amgen. H. Sorbye: Honoraria (self): Novartis; Honoraria (self): Ipsen; Honoraria (self): Pfizer; Honoraria (self): Keocyt; Honoraria (self): AstraZeneca; Honoraria (self): Roche; Honoraria (self): Amgen; Honoraria (self): Merck; Honoraria (self): Shire; Honoraria (self): Celgene; Honoraria (self): Nordic Drugs. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research